Toth Financial Advisory Corp Has $3.19 Million Stock Position in Quest Diagnostics Incorporated (NYSE:DGX)

Toth Financial Advisory Corp increased its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 1.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,570 shares of the medical research company’s stock after buying an additional 212 shares during the quarter. Toth Financial Advisory Corp’s holdings in Quest Diagnostics were worth $3,194,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DGX. Van Lanschot Kempen Investment Management N.V. acquired a new stake in Quest Diagnostics in the second quarter valued at $48,783,000. M&G Plc acquired a new stake in Quest Diagnostics in the 1st quarter valued at about $46,432,000. Vanguard Group Inc. grew its holdings in Quest Diagnostics by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock worth $1,853,151,000 after purchasing an additional 345,754 shares during the period. Wedge Capital Management L L P NC increased its position in Quest Diagnostics by 601.7% during the second quarter. Wedge Capital Management L L P NC now owns 277,561 shares of the medical research company’s stock worth $37,993,000 after buying an additional 238,007 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Quest Diagnostics by 222.0% in the second quarter. Point72 Asset Management L.P. now owns 299,740 shares of the medical research company’s stock valued at $41,028,000 after buying an additional 206,640 shares during the period. 88.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DGX has been the topic of a number of recent analyst reports. Truist Financial boosted their target price on Quest Diagnostics from $158.00 to $165.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Citigroup raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $145.00 to $165.00 in a research report on Wednesday, July 10th. Piper Sandler lifted their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a “neutral” rating in a report on Monday, July 29th. Robert W. Baird increased their price target on shares of Quest Diagnostics from $153.00 to $154.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, StockNews.com upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $154.92.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,990 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the sale, the senior vice president now directly owns 11,459 shares in the company, valued at $1,756,206.34. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of the business’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total transaction of $60,093.60. Following the completion of the transaction, the senior vice president now owns 5,019 shares of the company’s stock, valued at approximately $718,118.52. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Karthik Kuppusamy sold 1,990 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the transaction, the senior vice president now directly owns 11,459 shares of the company’s stock, valued at $1,756,206.34. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by insiders.

Quest Diagnostics Price Performance

Shares of DGX stock traded down $1.35 during trading on Monday, hitting $148.30. The company had a trading volume of 491,621 shares, compared to its average volume of 912,064. The stock’s 50-day moving average price is $152.67 and its 200 day moving average price is $144.09. Quest Diagnostics Incorporated has a one year low of $120.87 and a one year high of $159.36. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.91 and a current ratio of 1.00. The firm has a market capitalization of $16.47 billion, a P/E ratio of 20.14, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, July 23rd. The medical research company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.04. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.39 billion. Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%. Quest Diagnostics’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.30 EPS. Equities analysts expect that Quest Diagnostics Incorporated will post 8.89 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, October 21st. Investors of record on Friday, October 4th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Friday, October 4th. This represents a $3.00 annualized dividend and a dividend yield of 2.02%. Quest Diagnostics’s dividend payout ratio is 40.38%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.